Hightide
Latest round
- Series C
Last raised
- Jan 2023
Total raised
- $107M
Investors
- 14
About Hightide
Established in 2011 and based in Shenzhen, China, Hightide operates as a biopharmaceutical research and development company that focuses on the R&D of new drugs for metabolic and digestive diseases. It has R&D centres in the USA and China. Dr.S., and own10 IND submissions, and 100 patents. As of January 2023, HTD1801 has entered into a clinical 2 study.S. Food and Drug Administration (FDA) granted fast-track designation to HTD1801 for NASH and PSC. And HTD1801 was included in the National Major New Drug Innovation Program in China. The company focuses on therapeutic discovery, development and commercialization of multifunctional and multi-targeted therapies for metabolic and digestive diseases. It provides the molecular drug, HTD1801, for the treatment of type 2 diabetes (T2DM), nonalcoholic steatohepatitis (NASH), severe hypertriglyceridemia (SHTG), and primary sclerosing cholangitis (PSC).237 million.
Who invested in Hightide
14 investors across 3 rounds
See all investors in Hightide
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Hightide
Who invested in Hightide?
Hightide has 14 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Hightide raised?
Hightide has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Hightide last raise money?
Hightide's most recent round on record is a Series C, in Jan 2023.
What does Hightide do?
Established in 2011 and based in Shenzhen, China, Hightide operates as a biopharmaceutical research and development company that focuses on the R&D of new drugs for metabolic and digestive diseases.
Where is Hightide headquartered?
Hightide is headquartered in Shenzhen, China.
Which VCs invest in companies like Hightide?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Hightide's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Hightide? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.